How the Cancer biomarker Market Is Transforming Oncology Diagnostics
The Cancer biomarker Market is reshaping how oncologists diagnose and treat patients. Biomarkers offer reliable insights into tumor biology, allowing for earlier detection and more effective treatment planning.
From breast and lung cancers to rare malignancies, biomarkers are improving diagnostic accuracy. Combined with imaging techniques and genetic sequencing, they are making precision oncology a global reality.
Market Outlook: With a valuation of USD 15.9 billion in 2022, the market is projected to expand to USD 27.8 billion by 2030, advancing at 9.8% CAGR. This expansion highlights the increasing reliance on biomarker-driven oncology.